NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement under which healthcare providers that participate in the network of managed healthcare plan MultiPlan will offer access to GTG's BrevaGen breast cancer test.

The deal, executed by GTG's wholly owned subsidiary Phenogen Sciences, provides the company access to MultiPlan's network of 4,800 hospitals, 99,000 ancillary facilities, and 700,000 healthcare professionals across the US. MultiPlan is headquartered in Valencia, Calif., and covers approximately 39 million lives, GTG noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.